Temple Faculty Physicians is experiencing technical issues with phone lines. If you are experiencing an emergency, please visit your nearest emergency room. If you would like to schedule an appointment with your provider or have general questions or requests, please contact us by using myTempleHealth.

myTempleHealth
800-TEMPLE-MED Schedule Appointment
SEARCH TEMPLE HEALTH

Immunological Basis for Mepolizumab Activity in COPD

view all Clinical Trials

Overview

The current literature suggests that the mode of action of mepolizumab is to bind with Interleukin (IL)-5 and block the interaction of IL-5 with the IL-5Ra receptor on eosinophils. This removal of IL-5 may not explain all of the effects of mepolizumab. The investigators propose a set of studies to systematically examine the spectrum of effects of this drug on the immune system.

Clinical Trial Information

Protocol

TIRB#: 29478

Phase

2

Condition(s)

Chronic Obstructive Pulmonary Disease (COPD)

Investigator

Gerard Criner, MD

Coordinator

Dolores Fehrle

Visit clinicaltrials.gov for full description.

Contact

For more information about this trial or to inquire about eligibility, email [email protected] or call 215-707-1359.

Full Title

Immunological Basis for Mepolizumab Activity in COPD